Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
BC Cancer Agency · University of British Columbia · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
195
total citations
- FWCI
- 47.18
- Percentile
- 100%
- References
- 44
Citations per year
Authors
22- KCK.N. ChiCorresponding
BC Cancer Agency, University of British Columbia, Spinal Cord Injury BC
- SSShahneen Sandhu
The University of Melbourne, Peter MacCallum Cancer Centre
- MRMatthew R. Smith
Harvard University, Massachusetts General Hospital, Center for Cancer Research
- GAGerhardt Attard
Royal London Hospital, London Cancer, University College London
- MSMarniza Saad
University of Malaya
Topics & keywords
Topics
Keywords
- Medicine
- Abiraterone acetate
- Interim analysis
- Prednisone
- Prostate cancer
- Hazard ratio
- Internal medicine
- Progression-free survival
No related works found for this paper.
Funding
- ALAbbott Laboratories
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizerAward: GPP 2022
- AAstraZenecaAward: GPP 2022
- SSanofi
- GSGilead SciencesAward: GPP 2022
- CCelgene
- TPTaiho Pharmaceutical
- COClovis Oncology
- APAstellas Pharma
- IIpsen
- GGenentech
- TOTakeda Oncology
- JRJanssen Research and Development
- DSDaiichi Sankyo Europe